FEMSelect
Manufacturing · Israel · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2 Hama'ayan Fl 1, Modi’in, Tel Aviv, 717...Phone Number
+972 549456260Website
www.femselect.comRevenue
$7.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About FEMSelect
FEMSelect specializes in EnPlace, a minimally invasive treatment for Pelvic Organ Prolapse, targeting women over 50 who experience discomfort related to this condition. The EnPlace procedure is FDA-cleared, typically allows for same-day treatment, and aims to help patients quickly return to their daily activities. The company provides resources aimed at both patients and medical professionals, promoting awareness and education on the symptoms and management of Pelvic Organ Prolapse. With a focus on restoring quality of life, FEMSelect invites women seeking solutions to learn more about their innovative treatment options.Explore more
FEMSelect Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is FEMSelect your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if FEMSelect is spiking on competitors!
Check if FEMSelect has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on FEMSelect recently announced quarterly report
Funding: Get notified immidiatlly once FEMSelect has new funding data
Click to see if FEMSelect had a recent Job posting/layoffs
Product Launch: Get notified when FEMSelect launches new products
FEMSelect, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at FEMSelect
Recommended Actions
Reach out to Masked Content who joined FEMSelect as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
FEMSelect is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
FEMSelect is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about FEMSelect.
FEMSelect financials insights
Gather financial insights about FEMSelect, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series B
$9M
FEMSelect Tech Stack
A closer look at the technologies used by FEMSelect
See more technologies
Most Recent Scoops
Partnership
Project
Partnership, Product Management, Business Development, Logistics / Supply Chain, Healthcare Technology
Funding
Funding
New Hire
Executive Move
Funding
FEMSelect News & Media
FEMSelect Expands Women's Health Portfolio with Elidah Partnership to Distribute Elitone®
FDA-Cleared Elitone Incontinence Device Stops Bladder Leaks without Surgery or Medication NEW YORK, Sept. 25, 2025 /PRNewswire/ -- FEMSelect, a privately held women-led company revolutionizing women's pelvic health, today announced its expansion into the incontinence market through a...FEMSelect Closes Series B to Advance Pelvic Organ Prolapse Technology
FEMSelect, a company focused on pelvic organ prolapse (POP) treatment, has closed an oversubscribed Series B equity financing round to support commercial growth, leadership changes, and global expansion, the company announced today. The financing was led by existing investors New Age Ventures and Triventures, with participation from Robin Hood Ventures and RAD Biomed. New investorsFEMSelect Poised for Market Leadership with Strategic Advancements in Women's Health
FEMSelect Announces Close of Oversubscribed Series B Equity Financing to Drive Commercial Growth, Leadership Transformation, and Global Expansion NEW YORK, May 13, 2025 /PRNewswire/ -- FEMSelect, a privately held women-led company revolutionizing pelvic organ prolapse (POP) treatment with...New Study Reveals Promising Outcomes for Minimally Invasive Sacrospinous Ligament Fixation Using EnPlace® for Treating Pelvic Organ Prolapse in Older Women
NEWARK, Del., Oct. 17, 2024 (GLOBE NEWSWIRE) -- A new study published last week in the “Journal of Clinical Medicine” has revealed promising results for sacrospinous ligament (SSL) fixation using the EnPlace® device, a minimally invasive approach to pelvic organ prolapse (POP) repair.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding FEMSelect
Sign Up For FreeTo access detailed company insights
FEMSelect specializes in EnPlace, a minimally invasive treatment for Pelvic Organ Prolapse, targeting women over 50 who experience discomfort related to this condition. The EnPlace procedure is FDA-cleared, typically allows for same-day treatment, and aims to help patients quickly return to their daily activities. The company provides resources aim... Read More
